CXCR4-directed PET with 68Ga-pentixafor versus adrenal vein sampling for the diagnosis of unilateral primary aldosteronism

Objective To explore the accuracy of unilateral primary aldosteronism (UPA) classification via adrenal vein sampling (AVS) and C-X-C chemoking receptor 4 (CXCR4)-directed positron emission tomography (PET) with 68 Ga-pentixafor (CXCR4-directed molecular imaging). Methods A retrospective cohort study...

Full description

Saved in:
Bibliographic Details
Published inEndocrine Vol. 89; no. 2; pp. 603 - 613
Main Authors Tan, Lu, Chen, Tao, Zhang, Wenjie, Shen, Sikui, Tian, Haoming, Zhu, Yuchun, Tian, Rong, Ren, Yan
Format Journal Article
LanguageEnglish
Published New York Springer US 01.08.2025
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN1559-0100
1355-008X
1559-0100
DOI10.1007/s12020-025-04236-5

Cover

Abstract Objective To explore the accuracy of unilateral primary aldosteronism (UPA) classification via adrenal vein sampling (AVS) and C-X-C chemoking receptor 4 (CXCR4)-directed positron emission tomography (PET) with 68 Ga-pentixafor (CXCR4-directed molecular imaging). Methods A retrospective cohort study was conducted with 89 patients who were diagnosed with UPA and who underwent unilateral adrenalectomy (ADX) at West China Hospital of Sichuan University from January 2021 to June 2023. For these patients, surgical decisions were made on the basis of either AVS (AVS group) or CXCR4-directed molecular imaging (CXCR4 group), and patients were regularly followed up for more than 6 months after surgery. Whether biochemical and clinical success was achieved 6 months after surgery was determined on the basis of the primary aldosteronism surgical outcomes (PASO) criterion. The complete success rates were compared between the AVS group and CXCR4 group. One-way analysis of variance was used to compare preoperative factors, postoperative biochemical success rates and clinical success rates between the two groups. Additionally, the postoperative outcomes of adrenal nodules of different sizes were compared. Results 1. Among the 89 patients with UPA, 66 patients received ADX on the basis of AVS results, and 23 patients on the basis of CXCR4-directed molecular imaging results. The median age of the CXCR4 group [M ( P 25, P 75): 45.00 years (39.00, 51.00)] was significantly lower than that of the AVS group [M ( P 25, P 75): 49.00 years (40.75, 54.00)]. No significant differences in sex, history of hypertension, maximum blood pressure, antihypertensive drug defined daily dose (DDD), plasma aldosterone concentration (PAC), direct renin concentration (DRC), aldosterone-to-renin ratio (ARR), PAC after the captopril challenge test (CCT), PAC after the seated saline infusion test (SSIT), urea nitrogen, estimated glomerular filtration rate (eGFR), serum potassium level, diameter of the adrenal nodules or bilateral adrenal involvement were found. 2. There was no significant difference in the postoperative biochemical complete succcess rate (80.30 vs. 91.30%) or clinical cpmplete success rate (59.05 vs.65.21%) between the AVS group and the CXCR4 group. There were no significant differences in nitrogen, eGFR, serum potassium level, PAC, DRC, ARR, mean postoperative blood pressure or antihypertensive drug DDD after 6 months of follow-up. 3. For the identification of UPA patients with functional adrenal nodules ≥1 cm, CXCR4-directed molecular imaging have comparable diagnostic accuracies. 4. Three patients with adrenal micronodules achieved complete biochemical complete success after successful typing via CXCR4-directed molecular imaging, and unilateral aldosteronogenic micronodules were confirmed by immunohistochemistry (IHC) of CYP11B2 after surgery. Conclusion CXCR4-directed molecular imaging has high diagnostic value in diagnosing UPA. Patients with UPA diagnosed via CXCR4-directed molecular imaging achieved postoperative biochemical and clinical success, with outcomes that appear comparable to those of patients diagnosed on the basis of AVS. CXCR4-directed molecular imaging was more definitive for adrenal nodules larger than 1 cm.
AbstractList ObjectiveTo explore the accuracy of unilateral primary aldosteronism (UPA) classification via adrenal vein sampling (AVS) and C-X-C chemoking receptor 4 (CXCR4)-directed positron emission tomography (PET) with 68Ga-pentixafor (CXCR4-directed molecular imaging).MethodsA retrospective cohort study was conducted with 89 patients who were diagnosed with UPA and who underwent unilateral adrenalectomy (ADX) at West China Hospital of Sichuan University from January 2021 to June 2023. For these patients, surgical decisions were made on the basis of either AVS (AVS group) or CXCR4-directed molecular imaging (CXCR4 group), and patients were regularly followed up for more than 6 months after surgery. Whether biochemical and clinical success was achieved 6 months after surgery was determined on the basis of the primary aldosteronism surgical outcomes (PASO) criterion. The complete success rates were compared between the AVS group and CXCR4 group. One-way analysis of variance was used to compare preoperative factors, postoperative biochemical success rates and clinical success rates between the two groups. Additionally, the postoperative outcomes of adrenal nodules of different sizes were compared.Results1. Among the 89 patients with UPA, 66 patients received ADX on the basis of AVS results, and 23 patients on the basis of CXCR4-directed molecular imaging results. The median age of the CXCR4 group [M (P25, P75): 45.00 years (39.00, 51.00)] was significantly lower than that of the AVS group [M (P25, P75): 49.00 years (40.75, 54.00)]. No significant differences in sex, history of hypertension, maximum blood pressure, antihypertensive drug defined daily dose (DDD), plasma aldosterone concentration (PAC), direct renin concentration (DRC), aldosterone-to-renin ratio (ARR), PAC after the captopril challenge test (CCT), PAC after the seated saline infusion test (SSIT), urea nitrogen, estimated glomerular filtration rate (eGFR), serum potassium level, diameter of the adrenal nodules or bilateral adrenal involvement were found. 2. There was no significant difference in the postoperative biochemical complete succcess rate (80.30 vs. 91.30%) or clinical cpmplete success rate (59.05 vs.65.21%) between the AVS group and the CXCR4 group. There were no significant differences in nitrogen, eGFR, serum potassium level, PAC, DRC, ARR, mean postoperative blood pressure or antihypertensive drug DDD after 6 months of follow-up. 3. For the identification of UPA patients with functional adrenal nodules ≥1 cm, CXCR4-directed molecular imaging have comparable diagnostic accuracies. 4. Three patients with adrenal micronodules achieved complete biochemical complete success after successful typing via CXCR4-directed molecular imaging, and unilateral aldosteronogenic micronodules were confirmed by immunohistochemistry (IHC) of CYP11B2 after surgery.ConclusionCXCR4-directed molecular imaging has high diagnostic value in diagnosing UPA. Patients with UPA diagnosed via CXCR4-directed molecular imaging achieved postoperative biochemical and clinical success, with outcomes that appear comparable to those of patients diagnosed on the basis of AVS. CXCR4-directed molecular imaging was more definitive for adrenal nodules larger than 1 cm.
Objective To explore the accuracy of unilateral primary aldosteronism (UPA) classification via adrenal vein sampling (AVS) and C-X-C chemoking receptor 4 (CXCR4)-directed positron emission tomography (PET) with 68 Ga-pentixafor (CXCR4-directed molecular imaging). Methods A retrospective cohort study was conducted with 89 patients who were diagnosed with UPA and who underwent unilateral adrenalectomy (ADX) at West China Hospital of Sichuan University from January 2021 to June 2023. For these patients, surgical decisions were made on the basis of either AVS (AVS group) or CXCR4-directed molecular imaging (CXCR4 group), and patients were regularly followed up for more than 6 months after surgery. Whether biochemical and clinical success was achieved 6 months after surgery was determined on the basis of the primary aldosteronism surgical outcomes (PASO) criterion. The complete success rates were compared between the AVS group and CXCR4 group. One-way analysis of variance was used to compare preoperative factors, postoperative biochemical success rates and clinical success rates between the two groups. Additionally, the postoperative outcomes of adrenal nodules of different sizes were compared. Results 1. Among the 89 patients with UPA, 66 patients received ADX on the basis of AVS results, and 23 patients on the basis of CXCR4-directed molecular imaging results. The median age of the CXCR4 group [M ( P 25, P 75): 45.00 years (39.00, 51.00)] was significantly lower than that of the AVS group [M ( P 25, P 75): 49.00 years (40.75, 54.00)]. No significant differences in sex, history of hypertension, maximum blood pressure, antihypertensive drug defined daily dose (DDD), plasma aldosterone concentration (PAC), direct renin concentration (DRC), aldosterone-to-renin ratio (ARR), PAC after the captopril challenge test (CCT), PAC after the seated saline infusion test (SSIT), urea nitrogen, estimated glomerular filtration rate (eGFR), serum potassium level, diameter of the adrenal nodules or bilateral adrenal involvement were found. 2. There was no significant difference in the postoperative biochemical complete succcess rate (80.30 vs. 91.30%) or clinical cpmplete success rate (59.05 vs.65.21%) between the AVS group and the CXCR4 group. There were no significant differences in nitrogen, eGFR, serum potassium level, PAC, DRC, ARR, mean postoperative blood pressure or antihypertensive drug DDD after 6 months of follow-up. 3. For the identification of UPA patients with functional adrenal nodules ≥1 cm, CXCR4-directed molecular imaging have comparable diagnostic accuracies. 4. Three patients with adrenal micronodules achieved complete biochemical complete success after successful typing via CXCR4-directed molecular imaging, and unilateral aldosteronogenic micronodules were confirmed by immunohistochemistry (IHC) of CYP11B2 after surgery. Conclusion CXCR4-directed molecular imaging has high diagnostic value in diagnosing UPA. Patients with UPA diagnosed via CXCR4-directed molecular imaging achieved postoperative biochemical and clinical success, with outcomes that appear comparable to those of patients diagnosed on the basis of AVS. CXCR4-directed molecular imaging was more definitive for adrenal nodules larger than 1 cm.
To explore the accuracy of unilateral primary aldosteronism (UPA) classification via adrenal vein sampling (AVS) and C-X-C chemoking receptor 4 (CXCR4)-directed positron emission tomography (PET) with 68Ga-pentixafor (CXCR4-directed molecular imaging).OBJECTIVETo explore the accuracy of unilateral primary aldosteronism (UPA) classification via adrenal vein sampling (AVS) and C-X-C chemoking receptor 4 (CXCR4)-directed positron emission tomography (PET) with 68Ga-pentixafor (CXCR4-directed molecular imaging).A retrospective cohort study was conducted with 89 patients who were diagnosed with UPA and who underwent unilateral adrenalectomy (ADX) at West China Hospital of Sichuan University from January 2021 to June 2023. For these patients, surgical decisions were made on the basis of either AVS (AVS group) or CXCR4-directed molecular imaging (CXCR4 group), and patients were regularly followed up for more than 6 months after surgery. Whether biochemical and clinical success was achieved 6 months after surgery was determined on the basis of the primary aldosteronism surgical outcomes (PASO) criterion. The complete success rates were compared between the AVS group and CXCR4 group. One-way analysis of variance was used to compare preoperative factors, postoperative biochemical success rates and clinical success rates between the two groups. Additionally, the postoperative outcomes of adrenal nodules of different sizes were compared.METHODSA retrospective cohort study was conducted with 89 patients who were diagnosed with UPA and who underwent unilateral adrenalectomy (ADX) at West China Hospital of Sichuan University from January 2021 to June 2023. For these patients, surgical decisions were made on the basis of either AVS (AVS group) or CXCR4-directed molecular imaging (CXCR4 group), and patients were regularly followed up for more than 6 months after surgery. Whether biochemical and clinical success was achieved 6 months after surgery was determined on the basis of the primary aldosteronism surgical outcomes (PASO) criterion. The complete success rates were compared between the AVS group and CXCR4 group. One-way analysis of variance was used to compare preoperative factors, postoperative biochemical success rates and clinical success rates between the two groups. Additionally, the postoperative outcomes of adrenal nodules of different sizes were compared.1. Among the 89 patients with UPA, 66 patients received ADX on the basis of AVS results, and 23 patients on the basis of CXCR4-directed molecular imaging results. The median age of the CXCR4 group [M (P25, P75): 45.00 years (39.00, 51.00)] was significantly lower than that of the AVS group [M (P25, P75): 49.00 years (40.75, 54.00)]. No significant differences in sex, history of hypertension, maximum blood pressure, antihypertensive drug defined daily dose (DDD), plasma aldosterone concentration (PAC), direct renin concentration (DRC), aldosterone-to-renin ratio (ARR), PAC after the captopril challenge test (CCT), PAC after the seated saline infusion test (SSIT), urea nitrogen, estimated glomerular filtration rate (eGFR), serum potassium level, diameter of the adrenal nodules or bilateral adrenal involvement were found. 2. There was no significant difference in the postoperative biochemical complete succcess rate (80.30 vs. 91.30%) or clinical cpmplete success rate (59.05 vs.65.21%) between the AVS group and the CXCR4 group. There were no significant differences in nitrogen, eGFR, serum potassium level, PAC, DRC, ARR, mean postoperative blood pressure or antihypertensive drug DDD after 6 months of follow-up. 3. For the identification of UPA patients with functional adrenal nodules ≥1 cm, CXCR4-directed molecular imaging have comparable diagnostic accuracies. 4. Three patients with adrenal micronodules achieved complete biochemical complete success after successful typing via CXCR4-directed molecular imaging, and unilateral aldosteronogenic micronodules were confirmed by immunohistochemistry (IHC) of CYP11B2 after surgery.RESULTS1. Among the 89 patients with UPA, 66 patients received ADX on the basis of AVS results, and 23 patients on the basis of CXCR4-directed molecular imaging results. The median age of the CXCR4 group [M (P25, P75): 45.00 years (39.00, 51.00)] was significantly lower than that of the AVS group [M (P25, P75): 49.00 years (40.75, 54.00)]. No significant differences in sex, history of hypertension, maximum blood pressure, antihypertensive drug defined daily dose (DDD), plasma aldosterone concentration (PAC), direct renin concentration (DRC), aldosterone-to-renin ratio (ARR), PAC after the captopril challenge test (CCT), PAC after the seated saline infusion test (SSIT), urea nitrogen, estimated glomerular filtration rate (eGFR), serum potassium level, diameter of the adrenal nodules or bilateral adrenal involvement were found. 2. There was no significant difference in the postoperative biochemical complete succcess rate (80.30 vs. 91.30%) or clinical cpmplete success rate (59.05 vs.65.21%) between the AVS group and the CXCR4 group. There were no significant differences in nitrogen, eGFR, serum potassium level, PAC, DRC, ARR, mean postoperative blood pressure or antihypertensive drug DDD after 6 months of follow-up. 3. For the identification of UPA patients with functional adrenal nodules ≥1 cm, CXCR4-directed molecular imaging have comparable diagnostic accuracies. 4. Three patients with adrenal micronodules achieved complete biochemical complete success after successful typing via CXCR4-directed molecular imaging, and unilateral aldosteronogenic micronodules were confirmed by immunohistochemistry (IHC) of CYP11B2 after surgery.CXCR4-directed molecular imaging has high diagnostic value in diagnosing UPA. Patients with UPA diagnosed via CXCR4-directed molecular imaging achieved postoperative biochemical and clinical success, with outcomes that appear comparable to those of patients diagnosed on the basis of AVS. CXCR4-directed molecular imaging was more definitive for adrenal nodules larger than 1 cm.CONCLUSIONCXCR4-directed molecular imaging has high diagnostic value in diagnosing UPA. Patients with UPA diagnosed via CXCR4-directed molecular imaging achieved postoperative biochemical and clinical success, with outcomes that appear comparable to those of patients diagnosed on the basis of AVS. CXCR4-directed molecular imaging was more definitive for adrenal nodules larger than 1 cm.
Author Ren, Yan
Tian, Haoming
Tian, Rong
Zhang, Wenjie
Zhu, Yuchun
Chen, Tao
Tan, Lu
Shen, Sikui
Author_xml – sequence: 1
  givenname: Lu
  surname: Tan
  fullname: Tan, Lu
  organization: Department of Endocrinology and Metabolism, Adrenal Center, West China Hospital of Sichuan University
– sequence: 2
  givenname: Tao
  surname: Chen
  fullname: Chen, Tao
  organization: Department of Endocrinology and Metabolism, Adrenal Center, West China Hospital of Sichuan University
– sequence: 3
  givenname: Wenjie
  surname: Zhang
  fullname: Zhang, Wenjie
  organization: Department of Nuclear Medicine, West China Hospital of Sichuan University
– sequence: 4
  givenname: Sikui
  surname: Shen
  fullname: Shen, Sikui
  organization: Department of Urology, West China Hospital of Sichuan University
– sequence: 5
  givenname: Haoming
  surname: Tian
  fullname: Tian, Haoming
  organization: Department of Endocrinology and Metabolism, Adrenal Center, West China Hospital of Sichuan University
– sequence: 6
  givenname: Yuchun
  surname: Zhu
  fullname: Zhu, Yuchun
  organization: Department of Urology, West China Hospital of Sichuan University
– sequence: 7
  givenname: Rong
  surname: Tian
  fullname: Tian, Rong
  organization: Department of Nuclear Medicine, West China Hospital of Sichuan University
– sequence: 8
  givenname: Yan
  surname: Ren
  fullname: Ren, Yan
  email: renyan@scu.edu.cn
  organization: Department of Endocrinology and Metabolism, Adrenal Center, West China Hospital of Sichuan University
BookMark eNp9kUuLFDEUhYOMOA_9A64CbtxEb5JKUlmJNOMoDCgygruQVKW6M1QlbVI1o_56U3bjayEE8rjfOdybc45OYooeoacUXlAA9bJQBgwIMEGgYVwS8QCdUSE0gVo_-eN8is5LuQVgjEn1CJ02wNsW2uYMfd983nxsSB-y72bf4w-XN_g-zDss2ytL9j7O4asdUsZ3PpelYNtnH-1YryHiYqf9GOIWr8C887gPdhtTCQWnAS8xjHb2udL7HCabv2E79qnUpxRDmR6jh4Mdi39y3C_QpzeXN5u35Pr91bvN62vScc5nwq3TTPlBOaeHTjRgBXVaNYpqqx2V1gPvvVRDr6UYaLfO5RxIYRV0Trf8Ar06-O4XN_m-qzPVnsyxJ5NsMH9XYtiZbbozlLFWK1gdnh8dcvqy-DKbKZTOj6ONPi3FcAZCKspbWtFn_6C3acn1x1aK18UkNJViB6rLqZTsh1_dUDBrtuaQranZmp_ZGlFF_CAqFY5bn39b_0f1A-CDqNU
Cites_doi 10.2967/jnumed.121.261964
10.1016/S2213-8587(17)30135-3
10.1210/clinem/dgad654
10.3389/fendo.2024.1291775
10.1038/s41591-022-02114-5
10.1016/j.eprac.2020.10.016
10.1097/RLU.0000000000004244
10.1007/s12020-022-03122-8
10.1161/HYPERTENSIONAHA.117.09975
10.1530/ERC-21-0287
10.3389/fendo.2021.663096
10.1097/HJH.0000000000002510
10.1055/a-2106-4663
10.1177/02841851211034046
10.1001/jamanetworkopen.2022.55609
10.1097/HJH.0000000000003132
10.1210/clinem/dgaa379
10.1007/s00259-018-4076-2
10.1007/s00276-024-03331-y
10.1007/s00330-022-09058-x
10.1507/endocrj.EJ21-0508
10.2967/jnumed.119.234484
10.1053/j.semnuclmed.2023.09.002
10.1210/jc.2015-4061
10.2967/jnumed.121.262206
10.1038/s41574-022-00730-2
10.1007/s11307-021-01664-3
10.1210/clinem/dgad421
10.1210/clinem/dgaa484
10.3275/8818
10.3390/jcm10204755
ContentType Journal Article
Copyright The Author(s) 2025
The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2025. The Author(s).
The Author(s) 2025 2025
Copyright_xml – notice: The Author(s) 2025
– notice: The Author(s) 2025. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2025. The Author(s).
– notice: The Author(s) 2025 2025
DBID C6C
AAYXX
CITATION
K9.
NAPCQ
7X8
5PM
DOI 10.1007/s12020-025-04236-5
DatabaseName Springer Nature OA Free Journals
CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1559-0100
EndPage 613
ExternalDocumentID PMC12289708
10_1007_s12020_025_04236_5
GrantInformation_xml – fundername: the Science and Technology Department of Sichuan Province project
  grantid: NO.23ZDYF2116; NO.23ZDYF2116
– fundername: National Key Research and Development Program of China
  grantid: No.2021YFC2501601
  funderid: https://doi.org/10.13039/501100012166
GroupedDBID ---
-Y2
.86
.GJ
.VR
06C
06D
0R~
0VY
2.D
203
28-
29G
29~
2J2
2JN
2JY
2KG
2KM
2LR
2VQ
2~H
30V
4.4
406
408
40E
53G
5GY
5VS
78A
8TC
8UJ
95-
95.
95~
96X
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AAPKM
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBRH
ABDBE
ABDZT
ABECU
ABFSG
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABRTQ
ABSXP
ABTEG
ABTKH
ABTMW
ABWNU
ABXPI
ACAOD
ACCUX
ACDTI
ACGFO
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACREN
ACSNA
ACSTC
ACUDM
ACZOJ
ADHHG
ADHIR
ADHKG
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADZKW
AEBTG
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AEZWR
AFBBN
AFDZB
AFEXP
AFHIU
AFLOW
AFOHR
AFQWF
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGQPQ
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHPBZ
AHSBF
AHWEU
AI.
AIAGR
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AIXLP
AJBLW
AJRNO
AJZVZ
AKMHD
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
ATHPR
AVWKF
AXYYD
AYFIA
AZFZN
B-.
BA0
BBWZM
BDATZ
BGNMA
BSONS
C6C
CAG
COF
CS3
CSCUP
DDRTE
DNIVK
DPUIP
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ7
GRRUI
H13
HF~
HG6
HMJXF
HRMNR
HVGLF
HZ~
IJ-
IKXTQ
IMOTQ
IWAJR
IXD
I~X
I~Z
J-C
J0Z
JBSCW
JZLTJ
KOV
LLZTM
M4Y
MA-
N2Q
N9A
NDZJH
NF0
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OVD
P19
P2P
P9S
PF0
PT4
PT5
QOK
QOR
QOS
R4E
R89
R9I
RHV
RNI
ROL
RPX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TT1
TUC
U2A
U9L
UG4
UOJIU
UTJUX
UZXMN
VC2
VFIZW
VH1
W48
WK8
YLTOR
ZMTXR
ZOVNA
ZXP
~A9
~EX
~KM
AAYXX
CITATION
K9.
NAPCQ
7X8
5PM
ID FETCH-LOGICAL-c333t-3ab927ef7bb9fc540a51b974719a9b16ae03de67fd965f1c8084bb065a70cb983
IEDL.DBID C6C
ISSN 1559-0100
1355-008X
IngestDate Thu Aug 21 18:34:41 EDT 2025
Fri Sep 05 16:16:41 EDT 2025
Wed Sep 17 23:57:29 EDT 2025
Thu Jul 31 00:27:50 EDT 2025
Fri Jul 25 01:20:52 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Adrenal vein sampling
Ga-pentixafor
CXCR4-directed PET with
Unilateral primary aldosteronism
CXCR4-directed molecular imaging
Primary aldosteronism surgical outcomes (PASO)
Language English
License Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c333t-3ab927ef7bb9fc540a51b974719a9b16ae03de67fd965f1c8084bb065a70cb983
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://doi.org/10.1007/s12020-025-04236-5
PMID 40388084
PQID 3233232604
PQPubID 2043848
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_12289708
proquest_miscellaneous_3205671381
proquest_journals_3233232604
crossref_primary_10_1007_s12020_025_04236_5
springer_journals_10_1007_s12020_025_04236_5
PublicationCentury 2000
PublicationDate 2025-08-01
PublicationDateYYYYMMDD 2025-08-01
PublicationDate_xml – month: 08
  year: 2025
  text: 2025-08-01
  day: 01
PublicationDecade 2020
PublicationPlace New York
PublicationPlace_xml – name: New York
PublicationSubtitle International Journal of Basic and Clinical Endocrinology
PublicationTitle Endocrine
PublicationTitleAbbrev Endocrine
PublicationYear 2025
Publisher Springer US
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer Nature B.V
References B Liu (4236_CR11) 2021; 27
M Kircher (4236_CR27) 2020; 61
K Fujimoto (4236_CR19) 2013; 36
Z Yushi (4236_CR13) 2022; 13
H Wang (4236_CR32) 2021; 12
Y Gao (4236_CR8) 2023; 33
TA Williams (4236_CR2) 2017; 5
N Furuta (4236_CR18) 2015; 61
S Kumasaka (4236_CR17) 2022; 63
J Burrello (4236_CR23) 2020; 105
X Yin (4236_CR29) 2024; 15
TA Williams (4236_CR14) 2021; 106
J Ding (4236_CR33) 2022; 47
B Heinze (4236_CR7) 2018; 71
Y Zheng (4236_CR30) 2023; 109
L Lindenberg (4236_CR28) 2024; 54
TH Puar (4236_CR22) 2022; 40
S Kraus (4236_CR25) 2022; 63
X Wu (4236_CR21) 2023; 29
N Younes (4236_CR12) 2023; 131
T Derlin (4236_CR26) 2018; 45
S Samnani (4236_CR3) 2024; 109
G Ceolotto (4236_CR20) 2021; 10
AF Turcu (4236_CR1) 2022; 18
RE Brown (4236_CR35) 2022; 52
J Hu (4236_CR9) 2023; 6
JH Lin (4236_CR31) 2022; 29
J Ding (4236_CR34) 2022; 63
JW Funder (4236_CR5) 2016; 101
T Jia (4236_CR10) 2023; 31
M Naruse (4236_CR6) 2022; 69
P Mulatero (4236_CR4) 2020; 38
A Saadi (4236_CR15) 2024; 46
Z Chen (4236_CR24) 2022; 24
M Araujo-Castro (4236_CR16) 2022; 78
References_xml – volume: 63
  start-page: 368
  issue: 3
  year: 2022
  ident: 4236_CR34
  publication-title: J Nucl. Med
  doi: 10.2967/jnumed.121.261964
– volume: 5
  start-page: 689
  issue: 9
  year: 2017
  ident: 4236_CR2
  publication-title: Lancet Diabetes Endocrinol.
  doi: 10.1016/S2213-8587(17)30135-3
– volume: 109
  start-page: e1280
  issue: 3
  year: 2024
  ident: 4236_CR3
  publication-title: J Clin. Endocrinol. Metab.
  doi: 10.1210/clinem/dgad654
– volume: 15
  year: 2024
  ident: 4236_CR29
  publication-title: Front Endocrinol. (Lausanne)
  doi: 10.3389/fendo.2024.1291775
– volume: 29
  start-page: 190
  issue: 1
  year: 2023
  ident: 4236_CR21
  publication-title: Nat Med
  doi: 10.1038/s41591-022-02114-5
– volume: 27
  start-page: 326
  issue: 4
  year: 2021
  ident: 4236_CR11
  publication-title: Endocr Pr.
  doi: 10.1016/j.eprac.2020.10.016
– volume: 47
  start-page: 669
  issue: 8
  year: 2022
  ident: 4236_CR33
  publication-title: Clin Nucl. Med
  doi: 10.1097/RLU.0000000000004244
– volume: 78
  start-page: 363
  issue: 2
  year: 2022
  ident: 4236_CR16
  publication-title: Endocrine
  doi: 10.1007/s12020-022-03122-8
– volume: 71
  start-page: 317
  issue: 2
  year: 2018
  ident: 4236_CR7
  publication-title: Hypertension
  doi: 10.1161/HYPERTENSIONAHA.117.09975
– volume: 29
  start-page: 59
  issue: 2
  year: 2022
  ident: 4236_CR31
  publication-title: Endocr Relat. Cancer
  doi: 10.1530/ERC-21-0287
– volume: 12
  year: 2021
  ident: 4236_CR32
  publication-title: Front Endocrinol. (Lausanne)
  doi: 10.3389/fendo.2021.663096
– volume: 38
  start-page: 1919
  issue: 10
  year: 2020
  ident: 4236_CR4
  publication-title: J Hypertens.
  doi: 10.1097/HJH.0000000000002510
– volume: 131
  start-page: 418
  issue: 7-08
  year: 2023
  ident: 4236_CR12
  publication-title: Exp Clin. Endocrinol. Diabetes
  doi: 10.1055/a-2106-4663
– volume: 13
  start-page: 986
  issue: 6
  year: 2022
  ident: 4236_CR13
  publication-title: Medical J. Peking. Union Med. Coll. Hospital
– volume: 63
  start-page: 1276
  issue: 9
  year: 2022
  ident: 4236_CR17
  publication-title: Acta Radio.
  doi: 10.1177/02841851211034046
– volume: 61
  start-page: 185
  issue: 5
  year: 2015
  ident: 4236_CR18
  publication-title: Hinyokika Kiyo
– volume: 6
  start-page: e2255609
  issue: 2
  year: 2023
  ident: 4236_CR9
  publication-title: JAMA Netw. Open
  doi: 10.1001/jamanetworkopen.2022.55609
– volume: 40
  start-page: 1179
  issue: 6
  year: 2022
  ident: 4236_CR22
  publication-title: J Hypertens.
  doi: 10.1097/HJH.0000000000003132
– volume: 105
  start-page: dgaa379
  issue: 10
  year: 2020
  ident: 4236_CR23
  publication-title: J Clin. Endocrinol. Metab.
  doi: 10.1210/clinem/dgaa379
– volume: 45
  start-page: 1934
  issue: 11
  year: 2018
  ident: 4236_CR26
  publication-title: Eur J. Nucl. Med Mol. Imaging
  doi: 10.1007/s00259-018-4076-2
– volume: 46
  start-page: 543
  issue: 4
  year: 2024
  ident: 4236_CR15
  publication-title: Surg Radio. Anat.
  doi: 10.1007/s00276-024-03331-y
– volume: 33
  start-page: 996
  issue: 2
  year: 2023
  ident: 4236_CR8
  publication-title: Eur Radio.
  doi: 10.1007/s00330-022-09058-x
– volume: 69
  start-page: 327
  issue: 4
  year: 2022
  ident: 4236_CR6
  publication-title: Endocr J.
  doi: 10.1507/endocrj.EJ21-0508
– volume: 61
  start-page: 751
  issue: 5
  year: 2020
  ident: 4236_CR27
  publication-title: J Nucl. Med
  doi: 10.2967/jnumed.119.234484
– volume: 31
  start-page: 241
  issue: 3
  year: 2023
  ident: 4236_CR10
  publication-title: Chin J. Hypertens.
– volume: 54
  start-page: 163
  issue: 1
  year: 2024
  ident: 4236_CR28
  publication-title: Semin Nucl. Med
  doi: 10.1053/j.semnuclmed.2023.09.002
– volume: 52
  start-page: 27
  issue: 1
  year: 2022
  ident: 4236_CR35
  publication-title: Ann Clin. Lab Sci.
– volume: 101
  start-page: 1889
  issue: 5
  year: 2016
  ident: 4236_CR5
  publication-title: J Clin. Endocrinol. Metab.
  doi: 10.1210/jc.2015-4061
– volume: 63
  start-page: 96
  issue: 1
  year: 2022
  ident: 4236_CR25
  publication-title: J Nucl. Med
  doi: 10.2967/jnumed.121.262206
– volume: 18
  start-page: 665
  issue: 11
  year: 2022
  ident: 4236_CR1
  publication-title: Nat Rev. Endocrinol.
  doi: 10.1038/s41574-022-00730-2
– volume: 24
  start-page: 416
  issue: 3
  year: 2022
  ident: 4236_CR24
  publication-title: Mol Imaging Biol.
  doi: 10.1007/s11307-021-01664-3
– volume: 109
  start-page: 171
  issue: 1
  year: 2023
  ident: 4236_CR30
  publication-title: J Clin. Endocrinol. Metab.
  doi: 10.1210/clinem/dgad421
– volume: 106
  start-page: 42
  issue: 1
  year: 2021
  ident: 4236_CR14
  publication-title: J Clin. Endocrinol. Metab.
  doi: 10.1210/clinem/dgaa484
– volume: 36
  start-page: 564
  issue: 8
  year: 2013
  ident: 4236_CR19
  publication-title: J Endocrinol. Invest
  doi: 10.3275/8818
– volume: 10
  start-page: 4755
  issue: 20
  year: 2021
  ident: 4236_CR20
  publication-title: J Clin. Med
  doi: 10.3390/jcm10204755
SSID ssj0022267
Score 2.4268687
Snippet Objective To explore the accuracy of unilateral primary aldosteronism (UPA) classification via adrenal vein sampling (AVS) and C-X-C chemoking receptor 4...
ObjectiveTo explore the accuracy of unilateral primary aldosteronism (UPA) classification via adrenal vein sampling (AVS) and C-X-C chemoking receptor 4...
To explore the accuracy of unilateral primary aldosteronism (UPA) classification via adrenal vein sampling (AVS) and C-X-C chemoking receptor 4...
SourceID pubmedcentral
proquest
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 603
SubjectTerms Adrenalectomy
Aldosterone
Aldosterone synthase
Antihypertensives
Blood pressure
CXCR4 protein
Diabetes
Endocrinology
Epidermal growth factor receptors
Glomerular filtration rate
Humanities and Social Sciences
Immunohistochemistry
Internal Medicine
Medicine
Medicine & Public Health
multidisciplinary
Nodules
Original
Original Article
Patients
Positron emission tomography
Potassium
Renin
Sampling
Science
Surgery
Surgical outcomes
Title CXCR4-directed PET with 68Ga-pentixafor versus adrenal vein sampling for the diagnosis of unilateral primary aldosteronism
URI https://link.springer.com/article/10.1007/s12020-025-04236-5
https://www.proquest.com/docview/3233232604
https://www.proquest.com/docview/3205671381
https://pubmed.ncbi.nlm.nih.gov/PMC12289708
Volume 89
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1da9swFBVbC2MvY2s3lq0rGoy9bGK2ZMvSY2qSlo2WMRrInoxkSV0gVcqcjHa_fvc6TkLC-lAwNlgyEr76OEc694qQDzDFJiFwyZyrNctqI5gK3LK6BupTJPCiFWOeX8izUfZ1nI-7MDnoC7Ozf_-lSTkSHDx0FRUckuWPyX4OAy-25lKWa3IFMKLonGL-_932xLNBk7tayJ0N0XaeGT4nzzqASPtLi74gj3w8IIf9COT4-o5-pK1ks10LPyBPzrud8UPytxyXPzK2nKG8o98HlxTXWKlUp4bdoCbo1gBApSjDWDTUoAc3lPPHTyJtDOrK4xXFDIAIqVsK8CYNnQW6iJOpQUflKb1ZxqagZurQOQTj6jbXL8loOLgsz1h3rgKrhRBzJozVvPChsFaHGiCbyVOLvCLVRttUGp8I52URnJZ5SGuVqMxawCqmSGqrlXhF9uIs-teE-jRXPrgi1zxkRgM74UpJB4OEdS7XeY98Wv30qqtitQmUjCaqwERVa6IKch-t7FJ1XampBBdwAe3KeuT9Ohk6Ae5smOhnC8wDOA7otkp7RG3Zc10qhtHeTomTX2047ZQD6SwS1SOfV6bflH5_Zd88LPtb8pS3rRG1g0dkb_574d8BnpnbY7LfH56cXODz9Oe3wXHbsOE-4v1_HwXzng
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1NbxMxELWgSMAFQQsipYCREBewtGvvh32MopYATYVQIuW2std2iZQ6FZtUbX99Z5zdRKnggLSntVe2dvzxnufNmJCPsMUm3vOCWVsrltVaMOm5YXUN1KdM4EUUY47OiuEk-z7Np21QWNOp3TuXZFypt8FuHKkOXr-KWo6C5Q_JI3QzIuWa8P6GZgGgKNvwmL9_t7sFbXHlfVXkPddo3HFOnpNnLVSk_bVtX5AHLuyTg34AmnxxQz_RKN6Mp-L75PGo9ZEfkNvBdPArY-u9yln683hM8bSVFvKrZpeoDrrWAFUpCjJWDdUYyw3tXLlZoI1GhXk4p1gBsCG1aynerKELT1dhNtcYsjynl-ssFVTPLYaJYIbd5uIlmZwcjwdD1t6wwGohxJIJbRQvnS-NUb4G8Kbz1CDDSJVWJi20S4R1RemtKnKf1jKRmTGAWnSZ1EZJ8YrshUVwrwl1aS6dt2WuuM-0Ap7CpSwsLBfG2lzlPfK5--lV28VqmzIZTVSBiapoogpqH3V2qdpJ1VSCC3iAgGU98mFTDNMBfRw6uMUK6wCiA-It0x6RO_bctIoJtXdLwux3TKydcqCfZSJ75Etn-m3r_-7s4f9Vf0-eDMej0-r029mPN-QpjyMTFYVHZG_5Z-XeAspZmndxUN8ByBb2tQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwELZgSBMviG0gCmMYCfEC1hIncezHKVsZPzZNaJP6FtmxPSp1bkVaBPz13Dlpu07wgJSn-CJbOTv-Pt93F0LewBabeM8Fs7ZRLG90xqTnhjUNUJ8ygRtRjHl2Lk6v8k-jYnQriz-q3ZchyS6nAas0hfnhzPrDdeIbR9qDv2JFXYdgxX3yAGt1oaivEtWKcgG4KPtUmb8_t7kdrTHmXYXknTBp3H2Gj8mjHjbSo87PO-SeC7tk7ygAZb75Rd_SKOSMJ-S7ZPusj5fvkd_VqPqas27fcpZenFxSPHmlQn7QbIZKoZ8aYCtFccaipRrzuqGfH24caKtRbR6uKRoATqS2k-WNWzr1dBHGE43pyxM66ypWUD2xmDKC1XbbmyfkanhyWZ2y_m8LrMmybM4ybRQvnS-NUb4BIKeL1CDbSJVWJhXaJZl1ovRWicKnjUxkbgwgGF0mjVEye0q2wjS4Z4S6tJDO27JQ3OdaAWfhUgoLnw5jbaGKAXm3fOl1P8R6XT4ZXVSDi-roohqs95d-qfsF1tYZz-ACMpYPyOtVMywNjHfo4KYLtAF0ByRcpgMiN_y56hWLa2-2hPG3WGQ75UBFy0QOyPul69e9_3uwz__P_BXZvjge1l8-nn9-QR7yODFRXLhPtubfF-4lAJ65OYhz-g-vpvrk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CXCR4-directed+PET+with+68Ga-pentixafor+versus+adrenal+vein+sampling+for+the+diagnosis+of+unilateral+primary+aldosteronism&rft.jtitle=Endocrine&rft.au=Tan%2C+Lu&rft.au=Chen%2C+Tao&rft.au=Zhang%2C+Wenjie&rft.au=Shen%2C+Sikui&rft.date=2025-08-01&rft.pub=Springer+US&rft.eissn=1559-0100&rft.volume=89&rft.issue=2&rft.spage=603&rft.epage=613&rft_id=info:doi/10.1007%2Fs12020-025-04236-5&rft.externalDocID=10_1007_s12020_025_04236_5
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1559-0100&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1559-0100&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1559-0100&client=summon